Lexicon Pharmaceuticals Inc (LXRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.24-0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LXRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 41.5 | 49.8 | 31.1 | 1.2 | 0.1 | 0.3 | 24.0 | 0.1 | 63.2 | 91.7 | 79.3 | 130.0 | 22.9 | 2.2 | 1.1 | 1.8 |
| Total Revenues | 41.5 | 49.8 | 31.1 | 1.2 | 0.1 | 0.3 | 24.0 | 0.1 | 63.2 | 91.7 | 79.3 | 130.0 | 22.9 | 2.2 | 1.1 | 1.8 |
| Cost of Revenues | 0.4 | 0.3 | 0.6 | 0.1 | 0.0 | 0.0 | 1.9 | 0.0 | 2.5 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 35.3 | 37.3 | 143.1 | 114.0 | 48.1 | 32.3 | — | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 60.3 | 61.1 | 84.5 | 58.9 | 52.8 | 55.0 | 153.6 | 52.8 | 100.2 | 152.2 | 164.0 | 95.2 | 89.3 | 89.7 | 82.6 | 91.8 |
| Operating Income | (54.5) | (48.9) | (197.1) | (171.8) | (100.8) | (87.1) | (47.8) | (100.8) | (103.3) | (130.6) | (127.2) | 1.5 | (100.4) | (102.4) | (108.4) | (114.1) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | 2.8 | 0.8 | 14.5 | 2.8 | 20.8 | 7.0 | 6.6 | 6.7 | 2.3 | 2.0 | 2.1 | 2.5 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.2 | 0.2 | 0.3 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.8 | 1.9 | 2.3 |
| Asset Writedown | — | — | — | — | — | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 13.1 | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | (87.8) | (58.6) | (87.8) | (120.5) | (135.7) | (131.4) | (4.7) | (100.4) | — | (110.2) | (116.2) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.0 | 0.0 |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Net Income | (61.1) | (50.3) | (200.4) | (177.1) | (101.9) | (87.8) | (58.6) | (101.9) | (120.5) | (123.0) | (131.4) | (4.7) | (100.3) | (104.1) | (110.2) | (116.2) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.14) | (0.14) | (0.63) | (0.80) | (0.62) | (0.60) | (0.53) | (0.62) | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.14) | (0.14) | (0.63) | (0.80) | (0.62) | (0.60) | (0.53) | (0.60) | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 437.7 | 363.1 | 320.0 | 221.1 | 165.7 | 145.7 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 437.7 | 363.1 | 320.0 | 221.1 | 165.7 | 145.7 | 110.8 | 145.7 | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (48.3) | (196.6) | (171.2) | (100.3) | (86.8) | (44.9) | (100.3) | (99.6) | (127.2) | (125.1) | 2.2 | (98.4) | (99.5) | (104.2) | (109.2) |
| EBIT | (54.5) | (48.9) | (197.1) | (171.8) | (100.8) | (87.1) | (47.8) | (100.8) | (103.3) | (130.6) | (127.2) | 1.5 | (100.4) | (102.4) | (108.4) | (114.1) |
| Effective Tax Rate | — | — | — | — | — | 0.0% | — | — | — | 0.0% | 0.0% | 0.0% | 0.1% | — | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.